NTRK1 G595R

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Colorectal Adenocarcinoma1
LMNA::NTRK1 Fusion AND NTRK1 G595R AND NTRK1 G667C	Entrectinib	Predictive	C	Supports Resistance	4	accepted	EID2961 A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, an… (full text at CIViC) PMID 26546295 · Russo et al., 2016 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma1
NTRK1 G595R AND NTRK1 G667S	Larotrectinib	Predictive	C	Supports Resistance	2	accepted	EID9593 A 29-year-old male with NTRK-fusion positive NSCLC demonstrated initial response to Larotrectinib but progressed after devloping solvent-front (TRKA G595R) and xDFG (TRKA G667S) mutations. PMID 30624546 ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Colorectal Adenocarcinoma1

LMNA::NTRK1 Fusion AND NTRK1 G595R AND NTRK1 G667C

Entrectinib

Predictive

Supports Resistance

accepted

EID2961

A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, an… (full text at CIViC)

PMID 26546295 · Russo et al., 2016 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma1

NTRK1 G595R AND NTRK1 G667S

Larotrectinib

Predictive

Supports Resistance

accepted

EID9593

A 29-year-old male with NTRK-fusion positive NSCLC demonstrated initial response to Larotrectinib but progressed after devloping solvent-front (TRKA G595R) and xDFG (TRKA G667S) mutations.

PMID 30624546 ·

Malignant Neoplasm6
LMNA::NTRK1 Fusion AND NTRK1 G595R	Entrectinib	Predictive	D	Supports Resistance	3	accepted	EID11356 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, entrec… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
LMNA::NTRK1 Fusion AND NTRK1 G595R	Larotrectinib	Predictive	D	Supports Resistance	3	accepted	EID11350 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
LMNA::NTRK1 Fusion AND NTRK1 G595R	Repotrectinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID11347 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, repotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
LMNA::NTRK1 Fusion AND NTRK1 G595R AND NTRK1 F589L	Entrectinib	Predictive	D	Supports Resistance	3	accepted	EID11358 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, entrec… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
LMNA::NTRK1 Fusion AND NTRK1 G595R AND NTRK1 F589L	Larotrectinib	Predictive	D	Supports Resistance	3	rejected	EID11352 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, larotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
LMNA::NTRK1 Fusion AND NTRK1 G595R AND NTRK1 F589L	Larotrectinib	Predictive	D	Supports Resistance	3	accepted	EID11353 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, larotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic

Malignant Neoplasm6

LMNA::NTRK1 Fusion AND NTRK1 G595R

Entrectinib

Predictive

Supports Resistance

accepted

EID11356

In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, entrec… (full text at CIViC)

PMID 34625502 · Murray et al., 2021 · Open in CIViC

civic

LMNA::NTRK1 Fusion AND NTRK1 G595R

Larotrectinib

Predictive

Supports Resistance

accepted

EID11350

PMID 34625502 · Murray et al., 2021 · Open in CIViC

civic

LMNA::NTRK1 Fusion AND NTRK1 G595R

Repotrectinib

Predictive

Supports Sensitivity Response

accepted

EID11347

PMID 34625502 · Murray et al., 2021 · Open in CIViC

civic

LMNA::NTRK1 Fusion AND NTRK1 G595R AND NTRK1 F589L

Entrectinib

Predictive

Supports Resistance

accepted

EID11358

PMID 34625502 · Murray et al., 2021 · Open in CIViC

civic

LMNA::NTRK1 Fusion AND NTRK1 G595R AND NTRK1 F589L

Larotrectinib

Predictive

Supports Resistance

rejected

EID11352

PMID 34625502 · Murray et al., 2021 · Open in CIViC

civic

LMNA::NTRK1 Fusion AND NTRK1 G595R AND NTRK1 F589L

Larotrectinib

Predictive

Supports Resistance

accepted

EID11353

PMID 34625502 · Murray et al., 2021 · Open in CIViC

civic

Solid Neoplasm3
NTRK1 G595R	Larotrectinib	Predictive	B	Supports Resistance	3	submitted	EID7267 Patients with solid tumor that have a NTRK fusion were treated with larotrectinib. NTRK mutations were detected in patients with acquired resistance. Open in CIViC	civic
NTRK1 G595R	Selitrectinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID7269 Patients with solid tumor havoring NTRK fusion were treated with Larotrectinib. NTRK1 G595R mutation was deteceted in the tumor with acquired resistance. This patient was successfully treated with LOX… (full text at CIViC) Open in CIViC	civic
v::NTRK1 Fusion AND NTRK1 G595R	Larotrectinib	Predictive	A	Supports Resistance	3	submitted	EID11540 In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC	civic

Solid Neoplasm3

NTRK1 G595R

Larotrectinib

Predictive

Supports Resistance

submitted

EID7267

Patients with solid tumor that have a NTRK fusion were treated with larotrectinib. NTRK mutations were detected in patients with acquired resistance.

Open in CIViC

civic

NTRK1 G595R

Selitrectinib

Predictive

Supports Sensitivity Response

submitted

EID7269

Patients with solid tumor havoring NTRK fusion were treated with Larotrectinib. NTRK1 G595R mutation was deteceted in the tumor with acquired resistance. This patient was successfully treated with LOX… (full text at CIViC)

Open in CIViC

civic

v::NTRK1 Fusion AND NTRK1 G595R

Larotrectinib

Predictive

Supports Resistance

submitted

EID11540

In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

civic

Evidence by cancer (11 items)

Clinical significance (0)